Wessel van de Veerdonk1, Sarah Hoeck1,2, Marc Peeters3,4, Guido Van Hal1,2, Julie Francart5, Isabel De Brabander5. 1. Faculty of Medicine and Health Sciences, Department of Social Epidemiology and Health Policy, University of Antwerp, Antwerp, Belgium. 2. Centre for Cancer Detection, Bruges/Antwerp, Belgium. 3. Antwerp University Hospital, Oncology Department, Antwerp, Belgium. 4. Molecular Imaging, Pathology, Radiotherapy & Oncology, University of Antwerp, Belgium. 5. Belgian Cancer Registry, Brussels, Belgium.
Abstract
BACKGROUND: Colorectal cancer (CRC) and its precursor lesions are detected at an early stage by CRC screening programmes, which reduce CRC-related mortality. An important quality indicator for CRC screening is the occurrence of interval CRC (IC) between screening rounds. Currently there is no guideline regarding acceptable levels of ICs in CRC screening programmes, and ICs reported in prior work vary considerably. METHODS: This study describes the occurrence of screen-detected (SD) CRC and non-screen-detected CRC within the population-based CRC screening programme of Flanders, stratified by multiple variables such as sex, age, tumour location and tumour stage between October 2013 and July 2017. In addition, faecal immunochemical test (FIT) IC proportions over the sum of SD-CRCs and FIT-ICs are calculated, together with FIT sensitivity and programme sensitivity to display the effectiveness of detecting CRC by the screening programme. RESULTS: Of 1,212,354 FIT participants, 4094 were diagnosed with SD-CRC, whereas 772 participants were diagnosed with CRC between FIT-screening rounds. Significant associations were shown between people not being SD for CRC and women, older individuals, right-sided tumour location and more advanced tumour stage. Furthermore, a clear distinction was shown between the right-sided and the left-sided colorectum concerning all above-mentioned variables and distributions of tumour stages. CONCLUSION: The Flemish FIT-interval CRC proportion of 15.9% was within the limits of previously published results. In addition, calculations show that the effectiveness of the screening programme is dependent on tumour location, suggesting that future research should report results stratified by location.
BACKGROUND:Colorectal cancer (CRC) and its precursor lesions are detected at an early stage by CRC screening programmes, which reduce CRC-related mortality. An important quality indicator for CRC screening is the occurrence of interval CRC (IC) between screening rounds. Currently there is no guideline regarding acceptable levels of ICs in CRC screening programmes, and ICs reported in prior work vary considerably. METHODS: This study describes the occurrence of screen-detected (SD) CRC and non-screen-detected CRC within the population-based CRC screening programme of Flanders, stratified by multiple variables such as sex, age, tumour location and tumour stage between October 2013 and July 2017. In addition, faecal immunochemical test (FIT) IC proportions over the sum of SD-CRCs and FIT-ICs are calculated, together with FIT sensitivity and programme sensitivity to display the effectiveness of detecting CRC by the screening programme. RESULTS: Of 1,212,354 FIT participants, 4094 were diagnosed with SD-CRC, whereas 772 participants were diagnosed with CRC between FIT-screening rounds. Significant associations were shown between people not being SD for CRC and women, older individuals, right-sided tumour location and more advanced tumour stage. Furthermore, a clear distinction was shown between the right-sided and the left-sided colorectum concerning all above-mentioned variables and distributions of tumour stages. CONCLUSION: The Flemish FIT-interval CRC proportion of 15.9% was within the limits of previously published results. In addition, calculations show that the effectiveness of the screening programme is dependent on tumour location, suggesting that future research should report results stratified by location.
Entities:
Keywords:
Colorectal cancer screening; FIT; interval cancers; non–screen-detected colorectal cancers
Authors: Eline H Schreuders; Arlinda Ruco; Linda Rabeneck; Robert E Schoen; Joseph J Y Sung; Graeme P Young; Ernst J Kuipers Journal: Gut Date: 2015-06-03 Impact factor: 23.059
Authors: Manon van der Vlugt; Esmée J Grobbee; Patrick M M Bossuyt; Amanda Bos; Evelien Bongers; Wolfert Spijker; Ernst J Kuipers; Iris Lansdorp-Vogelaar; Manon C W Spaander; Evelien Dekker Journal: Gastroenterology Date: 2017-05-05 Impact factor: 22.682
Authors: Manuel Zorzi; Chiara Fedato; Grazia Grazzini; Fiorella Carmen Stocco; Flavio Banovich; Antonio Bortoli; Luigi Cazzola; Adriana Montaguti; Tina Moretto; Marco Zappa; Marcello Vettorazzi Journal: Gut Date: 2010-12-30 Impact factor: 23.059
Authors: Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman Journal: Lancet Date: 2018-01-31 Impact factor: 79.321
Authors: I Stegeman; S C van Doorn; M W Mundt; R C Mallant-Hent; E Bongers; M A G Elferink; P Fockens; A K Stroobants; P M Bossuyt; E Dekker Journal: Cancer Epidemiol Date: 2015-04-21 Impact factor: 2.984
Authors: Corrado R Asteria; Giuseppe Lucchini; Linda Guarda; Paolo Ricci; Mauro Pagani; Luigi Boccia Journal: Eur J Cancer Prev Date: 2019-01 Impact factor: 2.497
Authors: Jayne Digby; Callum G Fraser; Francis A Carey; Jaroslaw Lang; Greig Stanners; Robert Jc Steele Journal: J Med Screen Date: 2015-11-19 Impact factor: 2.136
Authors: M Garcia; X Domènech; C Vidal; E Torné; N Milà; G Binefa; L Benito; V Moreno Journal: Gastroenterol Res Pract Date: 2015-02-24 Impact factor: 2.260